Anticancer Activity in Heterocyclic Organic Structures A Pathway to Novel Drug Development Part 1

This new volume in New Directions in Organic & Biological Chemistry, explores the development of cancer therapeutics, focusing on molecular chemistry and advanced drug design approaches. Written by experts in theoretical chemistry and molecular chemistry, they bridge the gap between theoretical chemistry, molecular biology, and drug development. In Part I, they focus on the fundamental properties of heterocyclic compounds and innovative methodologies being employed to enhance therapeutic potential. By exploring various classes of heterocyclic compounds and diverse anticancer mechanisms, this book provides a valuable resource for researchers, pharmaceutical scientists, and oncologists.

Key Features

• Provides an overview of computational approaches used in drug discovery, including molecular docking, QSAR, and virtual screening
• Focuses on the theoretical and practical aspects of these techniques, with applications across various therapeutic areas, including cancer
• Addresses the challenges in translating scientific research into effective treatments, offering insights into overcoming common obstacles in the development process
• These compounds represent a significant opportunity for the pharmaceutical industry to provide more effective and tailored cancer treatments, further driving market growth
• The breadth of the market for heterocyclic anticancer agents is vast and continues to expand as scientific advancements uncover new therapeutic targets

Dr. Larbi EL Mchichi holds a PhD in Chemistry with a specialization in Theoretical Chemistry from Moulay Ismail University (Faculty of Sciences, Meknes). His doctoral research focused on the anticancer activity of heterocyclic organic molecules, using statistical and quantum methods, including QSAR modeling and molecular docking.

In his research, Dr. EL Mchichi explores innovative computational approaches to the design of novel therapeutic agents, particularly anticancer compounds, utilizing techniques like 3D-QSAR, drug-likeness assessment, ADMET prediction, and molecular docking simulations.

In addition to his research, he is a first-grade certified teacher of physics and chemistry at the secondary education level, where he strives to inspire his students with a passion for science and research.

Dr. EL Mchichi has authored several peer-reviewed publications in international journals, including work on the design of pyrazole derivatives as anticancer agents and the discovery of a new isatin scaffold for BCR-ABL tyrosine kinase inhibitors.

His research aims to contribute to the advancement of cutting-edge cancer therapies through the integration of computational methods and pharmaceutical science.